Halozyme Therapeutics Files 8-K
Ticker: HALO · Form: 8-K · Filed: Oct 1, 2025 · CIK: 1159036
| Field | Detail |
|---|---|
| Company | Halozyme Therapeutics, Inc. (HALO) |
| Form Type | 8-K |
| Filed Date | Oct 1, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, filing
Related Tickers: HALO
TL;DR
HALO filed an 8-K, looks like standard reporting.
AI Summary
On September 30, 2025, Halozyme Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No specific material events or financial figures were detailed in the provided excerpt.
Why It Matters
This filing indicates routine corporate reporting and disclosure by Halozyme Therapeutics, Inc. to the SEC.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any immediate material changes or risks.
Key Players & Entities
- HALOZYME THERAPEUTICS, INC. (company) — Registrant
- September 30, 2025 (date) — Date of Earliest Event Reported
- 12390 El Camino Real, San Diego, California 92130 (address) — Principal executive offices
- (858) 794-8889 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Halozyme Therapeutics, Inc.?
The filing is for Regulation FD Disclosure and Financial Statements and Exhibits, as indicated by the Item Information.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is September 30, 2025.
Where are Halozyme Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 12390 El Camino Real, San Diego, California 92130.
What is the Commission File Number for Halozyme Therapeutics, Inc.?
The Commission File Number is 001-32335.
What is the telephone number for Halozyme Therapeutics, Inc.?
The telephone number is (858) 794-8889.
Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-10-01 07:06:21
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value HALO The Nasdaq Stock Mar
Filing Documents
- d940775d8k.htm (8-K) — 25KB
- d940775dex991.htm (EX-99.1) — 40KB
- 0001193125-25-225853.txt ( ) — 184KB
- halo-20250930.xsd (EX-101.SCH) — 3KB
- halo-20250930_lab.xml (EX-101.LAB) — 17KB
- halo-20250930_pre.xml (EX-101.PRE) — 11KB
- d940775d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release of Halozyme Therapeutics, Inc., dated as of October 1, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HALOZYME THERAPEUTICS, INC. October 1, 2025 By: /s/ Nicole LaBrosse Name: Nicole LaBrosse Title: Senior Vice President, Chief Financial Officer